SSBP1积极调节RRM2,影响人类肺腺癌细胞的表皮介质转变和细胞循环停止
Xingyu Yang1, Bingfeng Ma1, Yafeng Liu1
1Department of Immunology, School of Medicine, Anhui University of Science and Technology, Huainan City, China; Anhui Province Engineering Laboratory of Occupational Health and Safety, School of Medicine, Anhui University of Science and Technology, Huainan City, China.
Cellular signalling
|December 6, 2024
概括
高SSBP1表达与肺腺癌 (LUAD) 的预后不佳相关. SSBP1通过上调RRM2来促进LUAD进展,这表明SSBP1/RRM2是潜在的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 肺腺癌 (LUAD) 的进展涉及表皮层-介质细胞过渡 (EMT) 和细胞周期变化.
- 确定新的预后生物标志物和治疗点对于改善LUAD患者的治疗结果至关重要.
研究的目的:
- 研究SSBP1在LUAD进展中的作用.
- 确定SSBP1作为潜在的预后生物标志物和LUAD中的治疗标.
主要方法:
- 对SSBP1表达和预后的癌症基因组图谱 (TCGA) 数据库的分析.
- 在体外研究:siRNA介导的SSBP1淘汰,细胞克隆,Transwell试验.
- 在体内小鼠模型中,评估SSBP1对瘤负担的淘汰效应.
- 机制研究:路径丰富分析和分子生物学技术,以确定下游目标.
主要成果:
- 在LUAD组织中高SSBP1表达与预后不佳有关 (AUC=0.853).
- 在实验室中,SSBP1 knockdown显著抑制了LUAD细胞的增殖,迁移和细胞循环进展,并在体内减少了瘤负担.
- RRM2被确定为SSBP1的下游目标,RRM2的淘汰模仿了SSBP1淘汰的影响.
结论:
- SSBP1通过增强EMT和细胞周期,部分通过RRM2调节,促进LUAD进展.
- SSBP1是LUAD的潜在预后生物标志物.
- SSBP1/RRM2轴代表了LUAD治疗的有前途的治疗标.
相关概念视频
Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K


